UK CAR-T firm Autolus provides update at ASH conference Autolus, which is a closely-watched chimeric antigen receptor T-cell therapy firm backed by three of the UK’s most prominent biotech investors, obtained an important validation of its technology recently with the publication of data on its dual targeting technology at the American Society of Hematology (ASH) conference over […]
John Laing Environmental buys Welsh wind farm – John Laing Environmental Assets has announced the acquisition of Llynfi Afan Wind Farm from John Laing Group for a cash consideration, including working capital, of GBP43.0 million. Llynfi Afan Wind Farm is located in the Afan Valley, Abergwynfi, West Glamorgan in Wales and comprises 12 Gamesa 2MW G80 turbines […]
Empiric Student Property parts ways with chief executive – the board of Empiric Student Property plc, has announced that Paul Hadaway, the company’s chief executive officer, has received notice to terminate his employment with the Company. Accordingly, Mr Hadaway has ceased to be a director of the company with immediate effect. Tim Attlee, co-founder and chief […]
Baillie Gifford-favourite Alnylam completes key US filing US biotech star and Baillie Gifford stock pick Alnylam Pharmaceuticals has completed its US regulatory application for patisiran, a treatment of adults with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), putting the so-called RNA interference or “gene-silencing” therapeutic on track for approval in mid 2018. Patisiran may become Alnylam’s first […]
MedicX dividend cover has some way to go – MedicX reports a 12.7% total return on EPRA NAV for the year ended 30 September 2017 as the EPRA NAV rose to 76.5p from 73.2p and EPRA earnings per share rose by 2.9% to 3.5p. The dividend of 6p, up from 5.95p was paid in four equal […]
Local Shopping REIT to continue with piecemeal liquidation – Local Shopping REIT has released results for the year ended 30 September 2017. The highlights are: IFRS Loss for the financial period of GBP0.86m or 1.04 pence per share (2016: Profit GBP0.63m or 0.76 pps). Adjusted operating profit for the period of GBP1.26m or 1.5 pps […]
Scottish Mortgage to benefit from Denali IPO – Baillie Gifford-managed Scottish Mortgage Investment Trust SMT looks set to receive a significant £85m windfall as a result of last week’s Nasdaq IPO of Denali Therapeutics, a US-based biotech in which it invested in 2016. Baillie Gifford was the lead investors in Denali’s $130m Series B financing round, investing […]
BioPharma Credit acquires royalty interest in diabetes drugs – In its third deal announced in rapid succession, BioPharma Credit has purchased from Royalty Pharma Investments (RPI) a 50% interest in a former Bristol-Myers Squibb-owned royalty stream on two AstraZeneca diabetes drugs. The royalty interested was acquired by RPI from Bristol Myers Squibb on 14 November 2017 and relates to sales of Onglyza […]
Scottish Investment Trust held back by contrarian style this year – Scottish Investment Trust says that, during the 12 months to 31 October 2017, the share price total return was 12.8% and the net asset value per share (NAV) total return (with borrowings at market value) was 11.0%. These returns include a 1.4p uplift from […]
Gilead reassures with CAR-T therapy durability data – Leading US biotech and investment company favourite Gilead Sciences has reassured investors with an important clinical trial update for its high profile cancer therapy Yescarta, which was obtained via the $12bn purchase of Kite Pharmaceuticals earlier this year. Longer follow-up data from 108 advanced lymphoma patients treated with Yescarta […]
